StockFacets
About
Sign-up
Sign-in
Earnings Calendar
Prices are updated after-hours
Published
Previous years
14
Publishing Date
2022 - 12 - 05
1
2022 - 08 - 24
1
2022 - 08 - 18
1
2022 - 08 - 08
1
2022 - 06 - 13
1
2022 - 04 - 11
1
2022 - 03 - 29
1
2022 - 02 - 24
1
2022 - 02 - 23
1
2021 - 12 - 07
1
2021 - 08 - 18
1
2021 - 07 - 26
1
2021 - 07 - 16
1
2021 - 06 - 07
1
Sector
Health technology
14
Tags
Alliances
9
Antibody
18
Application
17
Approval
41
Asco
7
Asia
8
Atopic dermatitis
9
Baricitinib
9
Biocapital
37
Business
8
Cancer
57
Car-t
11
Cel
9
Cell
11
Cell carcinoma
7
China
33
Chinese
25
Clinical-trials-phase-iii
12
Collaboration
19
Companies
24
Dermatitis
11
Designation
15
Disease
16
Drug
33
Earnings
21
Events
17
Expected
9
Fda
23
Financial
21
Financial results
13
Granted
7
Growth
34
Ibi351
9
Ibi362
12
Market
54
Medical
8
Meeting
16
N/a
279
New drug
9
Obesity
10
Pancreatic
7
People
10
Phase 1
14
Phase 2
19
Phase 3
23
Positive
15
Presentation
11
Report
13
Research
19
Results
72
Review
8
Study
37
T-cell
11
Therapeutics
20
Therapy
37
Treatment
77
Trial
28
Tumors
8
Tyvyt
9
Update
12
Entities
Eli lilly and company
13
Incyte corporation
14
Sanofi
3
Syndax pharmaceuticals, inc.
1
Symbols
ADXS
6
AFMD
9
AGNPF
6
AGTC
9
ALGS
7
ALLO
10
ALNY
7
ALT
7
ARAV
9
ARWR
14
BBIO
6
BLCM
7
BMY
10
BNTX
6
CGEN
7
CLDX
7
CLSD
6
COCP
7
CRNX
11
CUE
6
CVAC
6
CYAD
9
CYBN
11
DARE
8
DNLI
8
EYPT
8
FBIO
7
FDMT
8
IDYA
10
IGMS
7
IMAB
11
INAB
7
INCY
14
INZY
7
JNJ
10
LLY
24
MBIO
8
MBRX
17
MDNA
10
MORF
7
MRNA
10
NTLA
11
OCGN
7
OTIC
9
PSTV
7
PSTX
7
RAPT
8
RARE
10
REGN
9
RPTX
8
RUBY
12
SKYE
11
SLS
9
SNDX
7
SNY
33
SNYNF
26
SRNE
10
STRO
8
TEVJF
7
XNCR
7
Exchanges
Nasdaq
14
Nyse
13
Crawled Date
2022 - 12 - 05
1
2022 - 08 - 24
1
2022 - 08 - 18
1
2022 - 08 - 08
1
2022 - 06 - 13
1
2022 - 04 - 11
1
2022 - 03 - 29
1
2022 - 02 - 24
2
2021 - 12 - 07
1
2021 - 08 - 18
1
2021 - 07 - 26
1
2021 - 07 - 16
1
2021 - 06 - 07
1
Crawled Time
00:00
2
01:00
11
12:20
1
Source
www.biospace.com
2
www.prnewswire.com
12
Sort by:
after hours % change
|
delayed % change
|
gain open
|
gain high
|
gain close
|
publishing date
(GMT-12:00) International Date Line West
(GMT-11:00) American Samoa
(GMT-11:00) Midway Island
(GMT-10:00) Hawaii
(GMT-09:00) Alaska
(GMT-08:00) Pacific Time (US & Canada)
(GMT-08:00) Tijuana
(GMT-07:00) Arizona
(GMT-07:00) Chihuahua
(GMT-07:00) Mazatlan
(GMT-07:00) Mountain Time (US & Canada)
(GMT-06:00) Central America
(GMT-06:00) Central Time (US & Canada)
(GMT-06:00) Guadalajara
(GMT-06:00) Mexico City
(GMT-06:00) Monterrey
(GMT-06:00) Saskatchewan
(GMT-05:00) Bogota
(GMT-05:00) Eastern Time (US & Canada)
(GMT-05:00) Indiana (East)
(GMT-05:00) Lima
(GMT-05:00) Quito
(GMT-04:00) Atlantic Time (Canada)
(GMT-04:00) Caracas
(GMT-04:00) Georgetown
(GMT-04:00) La Paz
(GMT-04:00) Puerto Rico
(GMT-04:00) Santiago
(GMT-03:30) Newfoundland
(GMT-03:00) Brasilia
(GMT-03:00) Buenos Aires
(GMT-03:00) Greenland
(GMT-03:00) Montevideo
(GMT-02:00) Mid-Atlantic
(GMT-01:00) Azores
(GMT-01:00) Cape Verde Is.
(GMT+00:00) Casablanca
(GMT+00:00) Dublin
(GMT+00:00) Edinburgh
(GMT+00:00) Lisbon
(GMT+00:00) London
(GMT+00:00) Monrovia
(GMT+00:00) UTC
(GMT+01:00) Amsterdam
(GMT+01:00) Belgrade
(GMT+01:00) Berlin
(GMT+01:00) Bern
(GMT+01:00) Bratislava
(GMT+01:00) Brussels
(GMT+01:00) Budapest
(GMT+01:00) Copenhagen
(GMT+01:00) Ljubljana
(GMT+01:00) Madrid
(GMT+01:00) Paris
(GMT+01:00) Prague
(GMT+01:00) Rome
(GMT+01:00) Sarajevo
(GMT+01:00) Skopje
(GMT+01:00) Stockholm
(GMT+01:00) Vienna
(GMT+01:00) Warsaw
(GMT+01:00) West Central Africa
(GMT+01:00) Zagreb
(GMT+01:00) Zurich
(GMT+02:00) Athens
(GMT+02:00) Bucharest
(GMT+02:00) Cairo
(GMT+02:00) Harare
(GMT+02:00) Helsinki
(GMT+02:00) Jerusalem
(GMT+02:00) Kaliningrad
(GMT+02:00) Kyiv
(GMT+02:00) Pretoria
(GMT+02:00) Riga
(GMT+02:00) Sofia
(GMT+02:00) Tallinn
(GMT+02:00) Vilnius
(GMT+03:00) Baghdad
(GMT+03:00) Istanbul
(GMT+03:00) Kuwait
(GMT+03:00) Minsk
(GMT+03:00) Moscow
(GMT+03:00) Nairobi
(GMT+03:00) Riyadh
(GMT+03:00) St. Petersburg
(GMT+03:30) Tehran
(GMT+04:00) Abu Dhabi
(GMT+04:00) Baku
(GMT+04:00) Muscat
(GMT+04:00) Samara
(GMT+04:00) Tbilisi
(GMT+04:00) Volgograd
(GMT+04:00) Yerevan
(GMT+04:30) Kabul
(GMT+05:00) Ekaterinburg
(GMT+05:00) Islamabad
(GMT+05:00) Karachi
(GMT+05:00) Tashkent
(GMT+05:30) Chennai
(GMT+05:30) Kolkata
(GMT+05:30) Mumbai
(GMT+05:30) New Delhi
(GMT+05:30) Sri Jayawardenepura
(GMT+05:45) Kathmandu
(GMT+06:00) Almaty
(GMT+06:00) Astana
(GMT+06:00) Dhaka
(GMT+06:00) Urumqi
(GMT+06:30) Rangoon
(GMT+07:00) Bangkok
(GMT+07:00) Hanoi
(GMT+07:00) Jakarta
(GMT+07:00) Krasnoyarsk
(GMT+07:00) Novosibirsk
(GMT+08:00) Beijing
(GMT+08:00) Chongqing
(GMT+08:00) Hong Kong
(GMT+08:00) Irkutsk
(GMT+08:00) Kuala Lumpur
(GMT+08:00) Perth
(GMT+08:00) Singapore
(GMT+08:00) Taipei
(GMT+08:00) Ulaanbaatar
(GMT+09:00) Osaka
(GMT+09:00) Sapporo
(GMT+09:00) Seoul
(GMT+09:00) Tokyo
(GMT+09:00) Yakutsk
(GMT+09:30) Adelaide
(GMT+09:30) Darwin
(GMT+10:00) Brisbane
(GMT+10:00) Canberra
(GMT+10:00) Guam
(GMT+10:00) Hobart
(GMT+10:00) Melbourne
(GMT+10:00) Port Moresby
(GMT+10:00) Sydney
(GMT+10:00) Vladivostok
(GMT+11:00) Magadan
(GMT+11:00) New Caledonia
(GMT+11:00) Solomon Is.
(GMT+11:00) Srednekolymsk
(GMT+12:00) Auckland
(GMT+12:00) Fiji
(GMT+12:00) Kamchatka
(GMT+12:00) Marshall Is.
(GMT+12:00) Wellington
(GMT+12:45) Chatham Is.
(GMT+13:00) Nuku'alofa
(GMT+13:00) Samoa
(GMT+13:00) Tokelau Is.
tags :
Phase 1
symbols :
INCY
save search
Syndax Pharmaceuticals and Incyte Announce Axatilimab Phase 1/2 Data in Patients with Chronic Graft-Versus-Host Disease Published in the Journal of Clinical Oncology
Published:
2022-12-05
(Crawled : 12:20)
- biospace.com/
SNDX
|
$20.75
-2.49%
-2.55%
1.7M
|
Health Technology
|
-17.27%
|
O:
-0.28%
H:
4.28%
C:
1.76%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-36.58%
|
O:
-0.43%
H:
2.17%
C:
1.58%
pharmaceuticals
disease
phase 1
Innovent Announces First Patient Dosing in Australia in Phase 1 Study of IBI363 (PD-1/IL-2 Bispecific Antibody Fusion Protein) in Patients with Advanced Malignancies
Published:
2022-08-24
(Crawled : 01:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
9.06%
|
O:
-4.66%
H:
0.0%
C:
-1.69%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
138.26%
|
O:
0.43%
H:
1.39%
C:
0.76%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
12.64%
|
O:
-1.48%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-27.77%
|
O:
0.16%
H:
0.56%
C:
-0.19%
ibi363
australia
antibody
study
phase 1
Innovent Announces First Subject Dosed in Phase 1 Study of IBI311 (Anti-IGF-1R Monoclonal Antibody)
Published:
2022-08-18
(Crawled : 01:00)
- prnewswire.com
SNYNF
|
News
|
$92.116
-2.18%
2.3K
|
Health Technology
|
10.03%
|
O:
-5.88%
H:
3.23%
C:
3.23%
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
136.97%
|
O:
-0.02%
H:
0.7%
C:
-0.01%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
9.36%
|
O:
-1.55%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-28.62%
|
O:
-0.24%
H:
0.48%
C:
-0.08%
ibi311
study
phase 1
Innovent Announces First Patient Dosed in Phase 1 Study of IBI324 (VEGF-A/Ang-2 Bispecific Antibody) in Patients with Diabetic Macular Edema
Published:
2022-08-08
(Crawled : 01:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
149.16%
|
O:
-0.22%
H:
1.82%
C:
0.62%
SNY
|
News
|
$46.125
0.71%
0.7%
3.7M
|
Health Technology
|
-6.3%
|
O:
-0.14%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-26.94%
|
O:
0.0%
H:
2.7%
C:
2.55%
ibi324
macular
study
diabetic
phase 1
Innovent Releases Results of High-dose Cohorts in Phase 1 Clinical Study of Mazdutide (IBI362) in Chinese Adults with Overweight or Obesity at ENDO 2022
Published:
2022-06-13
(Crawled : 01:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
150.3%
|
O:
-3.12%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-26.35%
|
O:
-3.69%
H:
0.0%
C:
0.0%
ibi362
obesity
chinese
results
phase 1
Innovent Release Phase 1 Results of IBI322 (anti-PD-L1/CD47 bispecific antibody) in patients with advanced solid tumors at AACR Annual Meeting 2022
Published:
2022-04-11
(Crawled : 01:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
140.87%
|
O:
0.45%
H:
0.21%
C:
-1.32%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-36.62%
|
O:
-0.82%
H:
0.59%
C:
-1.88%
ibi322
results
antibody
phase 1
Innovent Announces First Patient Dosing of Claudin18.2/CD3 Bispecific Antibody IBI389 in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published:
2022-03-29
(Crawled : 01:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
157.41%
|
O:
0.13%
H:
0.38%
C:
-1.25%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-33.22%
|
O:
-0.05%
H:
1.43%
C:
1.01%
ibi389
trial
antibody
phase 1
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published:
2022-02-23
(Crawled : 01:00)
- biospace.com/
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
213.96%
|
O:
0.59%
H:
0.89%
C:
-0.93%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-22.66%
|
O:
0.87%
H:
0.84%
C:
-1.12%
cd73
trial
phase 1
antibody
phase 1b
Innovent Announces First Patient Dosed with CD73 Antibody in Phase 1a/1b Clinical Trial for Advanced Solid Tumor
Published:
2022-02-24
(Crawled : 01:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
215.04%
|
O:
-1.4%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-22.46%
|
O:
-1.25%
H:
1.21%
C:
1.04%
cd73
trial
phase 1
antibody
phase 1b
Innovent Releases Results of a Phase 1 Clinical Study of IBI362, a Dual Glucagon-like Peptide-1 and Glucagon Receptor Agonist in Chinese Patients with Type 2 Diabetes at the International Diabetes Federation Congress 2021
Published:
2021-12-07
(Crawled : 01:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
204.79%
|
O:
-0.84%
H:
0.49%
C:
0.36%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-20.42%
|
O:
-1.43%
H:
3.35%
C:
2.19%
chinese
diabetes
phase 1
results
Significant Weight Loss and Multiple Metabolic Benefits: Phase 1b Study Results of IBI362 in Chinese Participants with Overweight or Obesity Published in EClinicalMedicine by the Lancet
Published:
2021-08-18
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
175.3%
|
O:
-0.26%
H:
1.01%
C:
-1.28%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-30.32%
|
O:
-0.11%
H:
0.15%
C:
-1.38%
weight loss
chinese
obesity
phase 1
results
metabolic
phase 1b
lancet
phase 2b
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI321 (Anti-PD-1/TIGIT Bispecific Antibody) in Patients with Advanced Malignant Tumors
Published:
2021-07-26
(Crawled : 00:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
214.25%
|
O:
1.53%
H:
1.12%
C:
0.26%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-33.4%
|
O:
-0.49%
H:
0.51%
C:
-1.85%
phase 1
antibody
phase 2
Innovent Announces the First Patient Dosed in the Phase 1 Study of IBI319 (Anti-PD-1/CD137 Bispecific Antibody) in Patients with Advanced Malignant Tumors
Published:
2021-07-16
(Crawled : 01:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
224.35%
|
O:
0.21%
H:
0.0%
C:
0.0%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-34.09%
|
O:
0.3%
H:
0.44%
C:
-2.37%
phase 1
antibody
phase 2
Innovent Releases Phase 1 Results of Pemigatinib in Chinese Patients with Advanced Solid Tumors at ASCO Annual Meeting 2021
Published:
2021-06-07
(Crawled : 01:00)
- prnewswire.com
LLY
|
News
|
$750.77
0.54%
-0.04%
3.1M
|
Health Technology
|
271.63%
|
O:
-0.01%
H:
15.52%
C:
10.16%
INCY
|
$52.74
-0.9%
-0.91%
2.5M
|
Health Technology
|
-36.73%
|
O:
0.18%
H:
2.77%
C:
1.95%
chinese
solid tumors
phase 1
results
phase 3
phase 2
Gainers vs Losers
56%
44%
Top 10 Gainers
INVO
|
$1.76
131.58%
56.82%
230M
|
Health Technology
SINT
|
$0.0365
59.39%
37.26%
470M
|
Health Technology
WISA
4
|
$9.19
50.66%
33.7%
65M
|
Electronic Technology
EDBL
|
News
|
$6.73
47.91%
32.39%
13M
|
GCTK
|
$0.715
36.27%
26.62%
640K
|
Manufacturing
TCON
|
$2.33
36.26%
26.61%
2M
|
Health Technology
TIRX
|
$0.48
6.43%
24.58%
4.8M
|
KZIA
|
$0.38
30.58%
23.42%
300K
|
Health Technology
VNDA
|
News
|
$5.23
29.14%
22.56%
24M
|
Health Technology
ATNF
|
$1.91
29.05%
22.51%
310K
|
Your saved searches
Save your searches and get alerts when important news are released.